Resources
Discover articles, research, and published papers exploring the science, clinical applications, and evolving role of therapeutic apheresis in complex and chronic conditions.
Apheresis Blog Articles
Stamping Out Sepsis: A New Breakthrough Brings Hope to Millions
Integrative Treatments for Lyme Disease: Map Your Road to Recovery
What Is Apheresis
Apheresis-Related Published Research
July 2026
Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization
Results of 5 years of prospective follow-up confirm that LA has a lasting effect on prevention of cardiovascular events in patients with Lp(a)-HLP. Patients clinically selected by progressive cardiovascular disease were characterized by a highly frequent expression of small apo(a) isoforms. Only Lp(a) concentration seemed to comprehensively reflect Lp(a)-associated cardiovascular risk, however.
2017
Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels e A multicenter observational study
In conclusion to date LA is the only highly efficacious and safe treatment option for patients with marked elevation of Lp(a) (>600 mg/l or > 120 nmol/l) and progressive CVD. This study indicates that patients with raised Lp(a) appear to be at the highest CV risk before LA and benefit most from LA with the most marked CV event reduction rates in all vessel beds, compared to patients with isolated hypercholesterolemia. Further prospective studies to confirm these data are warranted
January 2026
Beyond lipids: Systemic effects of lipoprotein apheresis
The pleiotropic effects of LDL apheresis represent a fascinating convergence of lipid metabolism with inflammatory and hemostatic pathways. LA not only subtracts atherogenic lipoproteins but also acutely quiets inflammation, improves endothelial performance, thins the blood, and moderates immune activation
Published online: 15 March 2019
Lipoprotein(a) apheresis in patients with peripheral arterial disease: rationale and clinical results
Patients with symptomatic peripheral arterial disease (PAD) are at a very high risk of cardiovascular morbidity and mortality. Elevated lipoprotein(a) levels have been shown to be a risk factor for coronary artery disease (CAD) and stroke.
November 2017
Lipoprotein apheresis in patients with peripheral artery disease and lipoprotein(a)-hyperlipoproteinemia: 2-year follow-up of a prospective single center study
As early as 1 month after initiation of LA, all investigated parameters had improved significantly compared to baseline. This improvement was further substantiated under LA throughout the entire follow-up period.